Bone metastasis is the third most common condition in metastatic cancers and occurs in 60-65% of patients with metastatic cancers. The spine is the most common site of bone metastasis. Other common sites include ribs, skull, pelvis (hip bone), femur (leg bone) and humerus (arm bone). Bone metastatic cancers are rarely able to be cured, and treatment of bone metastasis involves medications to shrink, stop or slow down the growth of the tumor. Treatment options available for bone metastasis are symptomatic treatments which are meant for pain control, treatment, and prevention of fractures, improvement in functional disability, etc. Randomized trials on metastatic patients by UBM Medica, LLC showed that 45-75% patients develop functional disability every 3-4 months, 10-15% patients develop hypercalcemia and 10-20% patients develop long bone fractures.
Treatment of bone metastasis is the interdisciplinary field involving pain management, orthopedics, and other medical specialties. Primary factors driving the growth of bone metastasis therapeutics market are the global increase in cancer prevalence and delayed diagnosis of cancer in low-income countries. According to University of Texas Southwestern Medical Center Dallas, over 600,000 of bone metastasis are diagnosed in the U.S. every year. Rapid innovation in the field of personalized medicine and identification of new therapeutic targets for bone metastasis presents a huge opportunity to manufacturers of targeted therapy agents. A large number of treatment methods are still under investigation. However, heterogeneous nature of cancer and high development cost of neoplastic agents are the factors limiting the growth of global bone metastasis therapeutics market.
Market Analysis and Insights: Global Bone Metastasis Therapeutics Market
The global Bone Metastasis Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Bone Metastasis Therapeutics Scope and Market Size
Bone Metastasis Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Bone Metastasis Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
F. Hoffmann-La Roche
Bayer
Merck
Pfizer
Novartis
Amgen
Pharmalucence
Fresenius Kabi
Omega Laboratories
Eli Lilly
Bone Metastasis Therapeutics Breakdown Data by Type
Drug Treatment
Tumor Ablation Therapy
Surgery
Bone Metastasis Therapeutics Breakdown Data by Application
Hospitals
Cancer Rehabilitation Centers
Specialty Clinics
Ambulatory Surgical Centers
Treatment of bone metastasis is the interdisciplinary field involving pain management, orthopedics, and other medical specialties. Primary factors driving the growth of bone metastasis therapeutics market are the global increase in cancer prevalence and delayed diagnosis of cancer in low-income countries. According to University of Texas Southwestern Medical Center Dallas, over 600,000 of bone metastasis are diagnosed in the U.S. every year. Rapid innovation in the field of personalized medicine and identification of new therapeutic targets for bone metastasis presents a huge opportunity to manufacturers of targeted therapy agents. A large number of treatment methods are still under investigation. However, heterogeneous nature of cancer and high development cost of neoplastic agents are the factors limiting the growth of global bone metastasis therapeutics market.
Market Analysis and Insights: Global Bone Metastasis Therapeutics Market
The global Bone Metastasis Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Bone Metastasis Therapeutics Scope and Market Size
Bone Metastasis Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Bone Metastasis Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
F. Hoffmann-La Roche
Bayer
Merck
Pfizer
Novartis
Amgen
Pharmalucence
Fresenius Kabi
Omega Laboratories
Eli Lilly
Bone Metastasis Therapeutics Breakdown Data by Type
Drug Treatment
Tumor Ablation Therapy
Surgery
Bone Metastasis Therapeutics Breakdown Data by Application
Hospitals
Cancer Rehabilitation Centers
Specialty Clinics
Ambulatory Surgical Centers
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Bone Metastasis Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Bone Metastasis Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Drug Treatment
1.4.3 Tumor Ablation Therapy
1.4.4 Surgery
1.5 Market by Application
1.5.1 Global Bone Metastasis Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Rehabilitation Centers
1.5.4 Specialty Clinics
1.5.5 Ambulatory Surgical Centers
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Bone Metastasis Therapeutics Market Perspective (2015-2026)
2.2 Global Bone Metastasis Therapeutics Growth Trends by Regions
2.2.1 Bone Metastasis Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Bone Metastasis Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Bone Metastasis Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Bone Metastasis Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Bone Metastasis Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Bone Metastasis Therapeutics Players by Market Size
3.1.1 Global Top Bone Metastasis Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Bone Metastasis Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Bone Metastasis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Bone Metastasis Therapeutics Market Concentration Ratio
3.2.1 Global Bone Metastasis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Bone Metastasis Therapeutics Revenue in 2019
3.3 Bone Metastasis Therapeutics Key Players Head office and Area Served
3.4 Key Players Bone Metastasis Therapeutics Product Solution and Service
3.5 Date of Enter into Bone Metastasis Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Bone Metastasis Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Bone Metastasis Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Bone Metastasis Therapeutics Market Size by Application (2015-2020)
5.2 Global Bone Metastasis Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Bone Metastasis Therapeutics Market Size (2015-2020)
6.2 Bone Metastasis Therapeutics Key Players in North America (2019-2020)
6.3 North America Bone Metastasis Therapeutics Market Size by Type (2015-2020)
6.4 North America Bone Metastasis Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Bone Metastasis Therapeutics Market Size (2015-2020)
7.2 Bone Metastasis Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Bone Metastasis Therapeutics Market Size by Type (2015-2020)
7.4 Europe Bone Metastasis Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Bone Metastasis Therapeutics Market Size (2015-2020)
8.2 Bone Metastasis Therapeutics Key Players in China (2019-2020)
8.3 China Bone Metastasis Therapeutics Market Size by Type (2015-2020)
8.4 China Bone Metastasis Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Bone Metastasis Therapeutics Market Size (2015-2020)
9.2 Bone Metastasis Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Bone Metastasis Therapeutics Market Size by Type (2015-2020)
9.4 Japan Bone Metastasis Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Bone Metastasis Therapeutics Market Size (2015-2020)
10.2 Bone Metastasis Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Bone Metastasis Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Bone Metastasis Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Bone Metastasis Therapeutics Market Size (2015-2020)
11.2 Bone Metastasis Therapeutics Key Players in India (2019-2020)
11.3 India Bone Metastasis Therapeutics Market Size by Type (2015-2020)
11.4 India Bone Metastasis Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Bone Metastasis Therapeutics Market Size (2015-2020)
12.2 Bone Metastasis Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Bone Metastasis Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Bone Metastasis Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 F. Hoffmann-La Roche
13.1.1 F. Hoffmann-La Roche Company Details
13.1.2 F. Hoffmann-La Roche Business Overview
13.1.3 F. Hoffmann-La Roche Bone Metastasis Therapeutics Introduction
13.1.4 F. Hoffmann-La Roche Revenue in Bone Metastasis Therapeutics Business (2015-2020))
13.1.5 F. Hoffmann-La Roche Recent Development
13.2 Bayer
13.2.1 Bayer Company Details
13.2.2 Bayer Business Overview
13.2.3 Bayer Bone Metastasis Therapeutics Introduction
13.2.4 Bayer Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.2.5 Bayer Recent Development
13.3 Merck
13.3.1 Merck Company Details
13.3.2 Merck Business Overview
13.3.3 Merck Bone Metastasis Therapeutics Introduction
13.3.4 Merck Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.3.5 Merck Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer Bone Metastasis Therapeutics Introduction
13.4.4 Pfizer Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 Novartis
13.5.1 Novartis Company Details
13.5.2 Novartis Business Overview
13.5.3 Novartis Bone Metastasis Therapeutics Introduction
13.5.4 Novartis Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.5.5 Novartis Recent Development
13.6 Amgen
13.6.1 Amgen Company Details
13.6.2 Amgen Business Overview
13.6.3 Amgen Bone Metastasis Therapeutics Introduction
13.6.4 Amgen Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.6.5 Amgen Recent Development
13.7 Pharmalucence
13.7.1 Pharmalucence Company Details
13.7.2 Pharmalucence Business Overview
13.7.3 Pharmalucence Bone Metastasis Therapeutics Introduction
13.7.4 Pharmalucence Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.7.5 Pharmalucence Recent Development
13.8 Fresenius Kabi
13.8.1 Fresenius Kabi Company Details
13.8.2 Fresenius Kabi Business Overview
13.8.3 Fresenius Kabi Bone Metastasis Therapeutics Introduction
13.8.4 Fresenius Kabi Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.8.5 Fresenius Kabi Recent Development
13.9 Omega Laboratories
13.9.1 Omega Laboratories Company Details
13.9.2 Omega Laboratories Business Overview
13.9.3 Omega Laboratories Bone Metastasis Therapeutics Introduction
13.9.4 Omega Laboratories Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.9.5 Omega Laboratories Recent Development
13.10 Eli Lilly
13.10.1 Eli Lilly Company Details
13.10.2 Eli Lilly Business Overview
13.10.3 Eli Lilly Bone Metastasis Therapeutics Introduction
13.10.4 Eli Lilly Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.10.5 Eli Lilly Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Bone Metastasis Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Bone Metastasis Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Drug Treatment
1.4.3 Tumor Ablation Therapy
1.4.4 Surgery
1.5 Market by Application
1.5.1 Global Bone Metastasis Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Rehabilitation Centers
1.5.4 Specialty Clinics
1.5.5 Ambulatory Surgical Centers
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Bone Metastasis Therapeutics Market Perspective (2015-2026)
2.2 Global Bone Metastasis Therapeutics Growth Trends by Regions
2.2.1 Bone Metastasis Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Bone Metastasis Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Bone Metastasis Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Bone Metastasis Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Bone Metastasis Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Bone Metastasis Therapeutics Players by Market Size
3.1.1 Global Top Bone Metastasis Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Bone Metastasis Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Bone Metastasis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Bone Metastasis Therapeutics Market Concentration Ratio
3.2.1 Global Bone Metastasis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Bone Metastasis Therapeutics Revenue in 2019
3.3 Bone Metastasis Therapeutics Key Players Head office and Area Served
3.4 Key Players Bone Metastasis Therapeutics Product Solution and Service
3.5 Date of Enter into Bone Metastasis Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Bone Metastasis Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Bone Metastasis Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Bone Metastasis Therapeutics Market Size by Application (2015-2020)
5.2 Global Bone Metastasis Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Bone Metastasis Therapeutics Market Size (2015-2020)
6.2 Bone Metastasis Therapeutics Key Players in North America (2019-2020)
6.3 North America Bone Metastasis Therapeutics Market Size by Type (2015-2020)
6.4 North America Bone Metastasis Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Bone Metastasis Therapeutics Market Size (2015-2020)
7.2 Bone Metastasis Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Bone Metastasis Therapeutics Market Size by Type (2015-2020)
7.4 Europe Bone Metastasis Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Bone Metastasis Therapeutics Market Size (2015-2020)
8.2 Bone Metastasis Therapeutics Key Players in China (2019-2020)
8.3 China Bone Metastasis Therapeutics Market Size by Type (2015-2020)
8.4 China Bone Metastasis Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Bone Metastasis Therapeutics Market Size (2015-2020)
9.2 Bone Metastasis Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Bone Metastasis Therapeutics Market Size by Type (2015-2020)
9.4 Japan Bone Metastasis Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Bone Metastasis Therapeutics Market Size (2015-2020)
10.2 Bone Metastasis Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Bone Metastasis Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Bone Metastasis Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Bone Metastasis Therapeutics Market Size (2015-2020)
11.2 Bone Metastasis Therapeutics Key Players in India (2019-2020)
11.3 India Bone Metastasis Therapeutics Market Size by Type (2015-2020)
11.4 India Bone Metastasis Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Bone Metastasis Therapeutics Market Size (2015-2020)
12.2 Bone Metastasis Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Bone Metastasis Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Bone Metastasis Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 F. Hoffmann-La Roche
13.1.1 F. Hoffmann-La Roche Company Details
13.1.2 F. Hoffmann-La Roche Business Overview
13.1.3 F. Hoffmann-La Roche Bone Metastasis Therapeutics Introduction
13.1.4 F. Hoffmann-La Roche Revenue in Bone Metastasis Therapeutics Business (2015-2020))
13.1.5 F. Hoffmann-La Roche Recent Development
13.2 Bayer
13.2.1 Bayer Company Details
13.2.2 Bayer Business Overview
13.2.3 Bayer Bone Metastasis Therapeutics Introduction
13.2.4 Bayer Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.2.5 Bayer Recent Development
13.3 Merck
13.3.1 Merck Company Details
13.3.2 Merck Business Overview
13.3.3 Merck Bone Metastasis Therapeutics Introduction
13.3.4 Merck Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.3.5 Merck Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer Bone Metastasis Therapeutics Introduction
13.4.4 Pfizer Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 Novartis
13.5.1 Novartis Company Details
13.5.2 Novartis Business Overview
13.5.3 Novartis Bone Metastasis Therapeutics Introduction
13.5.4 Novartis Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.5.5 Novartis Recent Development
13.6 Amgen
13.6.1 Amgen Company Details
13.6.2 Amgen Business Overview
13.6.3 Amgen Bone Metastasis Therapeutics Introduction
13.6.4 Amgen Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.6.5 Amgen Recent Development
13.7 Pharmalucence
13.7.1 Pharmalucence Company Details
13.7.2 Pharmalucence Business Overview
13.7.3 Pharmalucence Bone Metastasis Therapeutics Introduction
13.7.4 Pharmalucence Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.7.5 Pharmalucence Recent Development
13.8 Fresenius Kabi
13.8.1 Fresenius Kabi Company Details
13.8.2 Fresenius Kabi Business Overview
13.8.3 Fresenius Kabi Bone Metastasis Therapeutics Introduction
13.8.4 Fresenius Kabi Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.8.5 Fresenius Kabi Recent Development
13.9 Omega Laboratories
13.9.1 Omega Laboratories Company Details
13.9.2 Omega Laboratories Business Overview
13.9.3 Omega Laboratories Bone Metastasis Therapeutics Introduction
13.9.4 Omega Laboratories Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.9.5 Omega Laboratories Recent Development
13.10 Eli Lilly
13.10.1 Eli Lilly Company Details
13.10.2 Eli Lilly Business Overview
13.10.3 Eli Lilly Bone Metastasis Therapeutics Introduction
13.10.4 Eli Lilly Revenue in Bone Metastasis Therapeutics Business (2015-2020)
13.10.5 Eli Lilly Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
